专论

转录因子ETS2在心血管疾病中的研究进展

展开
  • (北京大学基础医学院生理学与病理生理学系, 北京100191)
△ congxin@bjmu.edu.cn

收稿日期: 2025-05-14

  修回日期: 2025-06-11

  录用日期: 2025-06-12

  网络出版日期: 2026-02-25

基金资助

国家自然科学基金(31972908)资助课题

Advances of Transcription Factor ETS2 in Cardiovascular Diseases

Expand
  • (Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Beijing 100191, China)
△ congxin@bjmu.edu.cn

Received date: 2025-05-14

  Revised date: 2025-06-11

  Accepted date: 2025-06-12

  Online published: 2026-02-25

摘要

v-ets红母细胞病病毒E26原癌基因同源物2(v-ets erythroblastosis virus E26 oncogene homolog 2,ETS2)是一种转录因子,它广泛参与机体生长、发育等正常生理功能的调节以及肿瘤的发生。此外,ETS2的表达和活性异常也与心血管疾病的发生发展有着密切的关系。本文将对ETS2在心血管疾病研究领域中的最新进展进行综述,为今后探索心血管疾病的发生机制和开发治疗靶点提供新思路。

本文引用格式

李海兵, 丛 馨△ . 转录因子ETS2在心血管疾病中的研究进展[J]. 生理科学进展, 2026 , 57(1) : 79 -87 . DOI: 10.20059/j.cnki.pps.2025.07.1148

Abstract

v-ets erythroblastosis virus E26 oncogene homolog 2 (ETS2) is a transcription factor that plays a crucial role in regulating normal physiological processes such as growth and development, as well as in tumorigenesis. Moreover, aberrant expression and activity of ETS2 are closely associated with the pathogenesis and progression of cardiovascular diseases. This review summarizes the latest advances in ETS2 research within the context of cardiovascular diseases, providing new insights for future investigations into the pathogenesis of cardiovascular diseases and the development of therapeutic targets.
Options
文章导航

/